Role of interleukin-17A in the occurrence and treatment of psoriasis
- VernacularTitle:白细胞介素17A在银屑病发病及治疗中的研究进展
- Author:
Guannan ZHU
1
;
Gang WANG
Author Information
- From: Chinese Journal of Dermatology 2020;53(5):390-394
- CountryChina
- Language:Chinese
- Abstract: In the last 10 years, emerging evidence from basic researches and clinical trials has revealed and confirmed the critical role of Th17/interleukin-17A (IL-17A) in the occurrence of psoriasis. Besides affecting the proliferative activity and functions of keratinocytes, IL-17A also plays an important role in the regulation of immune cells and related cytokines in the immune microenvironment in psoriasis. In recent years, monoclonal antibodies targeting the IL-17A pathway, such as secukinumab, ixekizumab and brodalumab, have been successively marketed in China and other countries, and have exhibited marked efficacy in clinical practice. This review summarizes latest advances in the role of IL-17A in the pathogenesis of psoriasis as well as in biotherapies targeting IL-17A and its receptor IL-17RA.
